Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
453 produces sustained responses in a similar concentration range to those observed with acute stimulation (a small 1
03 μg/mL to 0
PubMed Central PMCID: PMC4397928
potent and cell-permeable inhibitor of p38 MAP kinase
Ruboxistaurin maintains the bone mass of subchondral bone for blunting osteoarthritis progression by inhibition of osteoclastogenesis and bone resorption activity
LY315920(Varespladib) endizoate 453 produces sustained responses inVarespladib, aslo known as LY315920, is a secreted phospholipase A2 (sPLA2) inhibitor (IC50 = 50 750 nM for a range of sPLA2 isoforms). Varespladib reduces atherosclerosis and aneurysm formation in ApoE mice and in guinea pigs. Varespladib significantly reduces the post ACS inflammatory response in those with and without diabetes. Varespladib may be potentially useful for treatment of coronary artery disease. Product information CAS Number: 172732 68
US$ 89.95
US$ 139.99
US$ 245.00
US$ 37.00
US$ 43.95